Quick Summary

The most studied drug: rifaximin. The American College of Gastroenterology (ACG) guideline lists it for SIBO at a regimen of 550 mg three times a day, usually for ~14 days, with a reported efficacy of 61-78% [1][3].
Methane (IMO) is different: because it is produced by archaea rather than typical bacteria, the literature describes combining rifaximin + neomycin (neomycin 500 mg twice a day). In one study, the combination reduced methane in 87% of cases, compared with 33% for neomycin alone [1][3].
This is education, not a prescription. These are prescription drugs: naming doses here is meant to help you understand your report and your conversations with your doctor, not to self-medicate.

💡 Which antibiotics are used for SIBO, and on what regimen?

For hydrogen SIBO, the ACG guideline lists rifaximin 550 mg three times a day (reported efficacy 61-78%), usually for about 14 days. For methane or IMO, the literature describes combining rifaximin with neomycin 500 mg twice a day, because methane is produced by archaea and rifaximin alone is less effective. Metronidazole (250 mg three times a day) appears as a systemic alternative. The choice, dose, and duration are decided by a professional based on your case.

Antibiotics for SIBO: Drugs, Regimens, and Evidence

If you’ve been diagnosed with SIBO (small intestinal bacterial overgrowth) or IMO (intestinal methanogen overgrowth, the “methane” pattern), the concrete question is probably: which antibiotic, how much, and for how long? This guide answers that with the numbers that appear in the clinical guidelines and in peer-reviewed studies, citing the exact source of each figure.

An important framing note: this is educational information, not a prescription. Naming rifaximin and its dose doesn’t tell you whether you need treatment, nor does it replace a gastroenterologist’s evaluation. But hiding the dose doesn’t help you either: knowing what the evidence describes lets you understand your report, read your prescription with discernment, and ask better questions during your visit.

Author’s note: I’m not a doctor. I built sibowise.com when a close relative was diagnosed with SIBO and I had to do my own research to support them through the process. What frustrated me most was finding pages that repeated “consult your doctor” without daring to even name which drug is used, while the prescription already said “rifaximin” and I didn’t understand why that one and not another, nor why the methane regimen was different. This guide is the one I would have liked to read back then: one that explains what the sources say, with their numbers and their limits, without treating you as if you couldn’t handle the information.

If you’re still wrapping your head around the diagnosis, it’s worth first reading what SIBO is and how the breath test works.

The Test Pattern Changes the Drug

Before the table, there’s one idea that organizes everything else: treatment is not the same for hydrogen as for methane. The breath test measures gases indirectly, and according to the North American Consensus cited by the ACG:

Hydrogen (H₂): a rise of 20 ppm or more above baseline within the first 90 minutes is considered compatible with SIBO [1].
Methane (CH₄): a level of 10 ppm or more at any point during the test is indicative of methanogen overgrowth (IMO) [1].

Methane is produced by archaea (mainly Methanobrevibacter smithii), which are not bacteria and don’t respond the same way to an antibiotic designed for bacteria. That’s why the approach to methane usually adds a second drug. If your report mentions methane, the guide methane SIBO vs. hydrogen explains that difference in detail.

Table: Antibiotics Described by the ACG Guideline

The American College of Gastroenterology clinical guideline (Pimentel et al., 2020) includes a table of antibiotics suggested for SIBO with their doses and efficacy ranges. These are the verbatim data from that source [1]:

Drug	Dose (per ACG)	Reported efficacy	Notes
Rifaximin (non-absorbable)	550 mg, 3 times a day	61-78%	The most studied. Acts locally in the gut, with little systemic absorption. The usual first choice for H₂.
Metronidazole	250 mg, 3 times a day	43-87%	Systemic antibiotic. An alternative, also used in some methane regimens.
Neomycin	500 mg, 2 times a day	33-55% (alone)	Key in IMO/methane, but combined with rifaximin, not alone. Risk of oto/nephrotoxicity limits prolonged use.
Ciprofloxacin	500 mg, 2 times a day	43-100%	Systemic antibiotic, less commonly used as first line.
Amoxicillin-clavulanate	875 mg, 2 times a day	~50%	Systemic.
Tetracycline	250 mg, 4 times a day	~87.5%	Systemic; data from a single small study.
Trimethoprim-sulfamethoxazole	160/800 mg, 2 times a day	~95%	Systemic; data from a study in children combined with metronidazole.

Two honest caveats about this table, which the guideline itself flags:

Efficacy is slippery. The ACG notes that rifaximin studies varied widely: doses from 600 to 1,600 mg per day and durations from 5 to 28 days, and only one compared rifaximin against placebo [1]. The wide ranges (e.g., ciprofloxacin “43-100%”) reflect small, heterogeneous studies, not a guarantee. That’s why the recommendation to use antibiotics in SIBO is conditional, with a low level of evidence [1].
Not all of them are good for the same thing. Rifaximin leads for hydrogen; methane needs a different approach.

The Typical Rifaximin Regimen for Hydrogen SIBO

When people talk about “the SIBO treatment,” they almost always mean rifaximin. The most cited regimen:

Rifaximin 550 mg, three times a day, for approximately 14 days (equivalent to 1,650 mg/day for 2 weeks).

The 550 mg three-times-a-day dose comes from the ACG table [1], and the ~2-week duration (1,650 mg/day) is the one the StatPearls/NCBI review describes as an effective regimen for hydrogen SIBO [3]. Rifaximin is a non-absorbable antibiotic: it acts mostly within the gut and barely passes into the bloodstream, which explains why it’s usually tolerated better than systemic antibiotics [1][3]. Even so, it remains a prescription drug with contraindications and interactions.

The Regimen for Methane (IMO): Rifaximin + Neomycin

Here is the most important difference and the one that causes the most confusion. Because methanogenic archaea are not bacteria, rifaximin alone does little against methane. The literature describes combining it with neomycin:

Rifaximin + neomycin 500 mg twice a day, for about 2 weeks.

The most cited evidence is a study by Low et al. (74 patients with IMO) that the ACG summarizes as follows [1][4]: with 10 days of treatment, reduction of methane to undetectable levels was 33% with neomycin alone, 28% with rifaximin alone, and 87% with both antibiotics combined. In other words, synergy matters: neither drug on its own matched the combination.

StatPearls frames it as neomycin 1,000 mg/day + rifaximin 1,650 mg/day for 2 weeks for the methane pattern [3]. Metronidazole (250 mg three times a day) appears as an alternative to neomycin in some regimens, depending on the case and contraindications [1].

A point of precision: the neomycin studies in IMO used a methane threshold of 3 ppm or more to define positivity, not the 10 ppm or more recommended today by the North American Consensus [1]. That’s why the eradication percentages should be read with that context, not as universal figures.

Why It Isn’t Decided by a Symptom List Alone

Bloating, gas, pain, diarrhea, or constipation appear in SIBO, but also in irritable bowel syndrome, intolerances, celiac disease, inflammatory bowel disease, functional constipation, dyspepsia, and motility disorders. That’s why a professional doesn’t prescribe an antibiotic based on the symptom list alone: they integrate clinical history, the test pattern (H₂, methane/IMO, or mixed), background factors (abdominal surgery, diabetes, hypothyroidism, opioid use), and the possibility that the picture is better explained by another diagnosis [1][2].

The AGA Clinical Practice Update (Quigley, Murray, Pimentel, 2020) is explicit that the definition of SIBO has limits and that the evidence for several antibiotic strategies is limited; it recommends considering the underlying causes and the risks of antibiotic use, not just “giving the drug” [2].

Recurrence Is Common: The Antibiotic Doesn’t Close the Case

One fact worth having from the start: SIBO often recurs after being treated. In a study of 80 adults cited by the ACG, recurrence rates were 12.6% at 3 months, 27.5% at 6 months, and 43.7% at 9 months [1]. The guideline notes that re-treating with another course of antibiotics is common practice, but it is based on expert opinion rather than solid trials [1].

That’s why the antibiotic is rarely the whole story. If symptoms return, it usually makes more sense to look for the factor that’s maintaining them—slow motility, constipation, altered anatomy, an underlying disease—than to repeat courses blindly. Motility is addressed in the guide on the migrating motor complex and SIBO and in the one on prokinetics.

Limits and Risks Worth Keeping in Mind

Even when properly indicated, antibiotics don’t correct motility disorders, persistent constipation, structural causes, or habits that worsen symptoms. And breath tests are indirect: they can be affected by intestinal transit, prior preparation, and the substrate used [5]. Some people improve completely, others partially, and others get no clear benefit.

Before starting any antibiotic, it’s worth discussing with the professional:

Allergies or previous reactions to medications.
Pregnancy, trying to conceive, or breastfeeding.
Kidney, liver, hearing, or neurological disease (especially relevant with neomycin, given its risk of oto- and nephrotoxicity).
Use of anticoagulants, anticonvulsants, lithium, or other drugs.
A history of antibiotic-associated diarrhea or Clostridioides difficile infection.
Supplements, herbs, and probiotics that may interact.

If you’re already taking a prescribed antibiotic and an allergic reaction, difficulty breathing, severe diarrhea, blood in the stool, high fever, severe abdominal pain, or dehydration appears, contact your treating team or seek urgent care depending on the severity.

Diet and Probiotics During the Process

Diet can help manage symptoms but does not replace medical evaluation. The ACG mentions that the predominant dietary approach in SIBO is to reduce fermentables, although the evidence comes largely from studies in IBS [1]. Some people use a low-FODMAP diet temporarily and under supervision. With probiotics something similar happens: they can help in certain contexts and worsen symptoms in others. Before combining products with antibiotics, review the decision with your professional.

Concrete Questions for Your Appointment

Does my test suggest hydrogen, methane/IMO, a mixed pattern, or something inconclusive, and does that change which antibiotic suits me?
If it’s methane, is combining rifaximin with neomycin or metronidazole being considered?
What dose and duration do you propose, and why?
How will we measure the response (symptoms, breath retest)?
If symptoms return, will we look for underlying factors such as motility or constipation before repeating antibiotics?
Are there medications, supplements, or conditions (kidney, hearing, pregnancy) that change the decision in my case?

In Summary

Antibiotics do have a defined role in SIBO and IMO, and the evidence is concrete enough to name them: rifaximin 550 mg three times a day for the hydrogen pattern, and rifaximin combined with neomycin for methane. But that same evidence is honest about its limits: a conditional level of recommendation, variable efficacy, and frequent recurrence. Understanding those numbers—rather than hiding them—is what allows you to have a genuinely useful clinical conversation.

Disclaimer: this guide is educational and summarizes public sources. It does not diagnose or prescribe. Doses are cited so you understand the evidence, not so you self-medicate: only a healthcare professional can prescribe, adjust, or discontinue an antibiotic based on your case.

References

Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-178. PubMed
Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020;159(4):1526-1532. PubMed
Sorathia SJ, Chippa V, Rivas JM. Small Intestinal Bacterial Overgrowth. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated 2023. NCBI Bookshelf
Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547-550. PubMed
Mayo Clinic. An updated appraisal of the SIBO hypothesis and the limits of breath testing. 2024. Mayo Clinic

Antibiotics for SIBO: Which Drugs, Regimens, and Evidence

Editorial standards for this guide